Not surprisingly, therapies that induced epigenetic-based differentiation of AML into homogeneous lineage states, such as IDH1, IDH2 and menin inhibitors90–93 have demonstrated promising therapeutic options in AML. This evidence concerns the gene IDH2 and acute myeloid leukemia.